B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models

Vascular Permeability in Cerebral Cavernous Malformations

(2015) Abdul G Mikati et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Polymorphisms in Inflammatory and Immune Response Genes Associated with Cerebral Cavernous Malformation Type 1 Severity

(2014) Hélène Choquet et al.   CEREBROVASCULAR DISEASES

Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations

(2014) Robert Shenkar et al.   GENETICS IN MEDICINE

Evaluation of Iron Content in Human Cerebral Cavernous Malformation Using Quantitative Susceptibility Mapping

(2014) Huan Tan et al.   INVESTIGATIVE RADIOLOGY

The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation

(2014) Dong Lu et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Immune complex formation and in situ B-cell clonal expansion in human cerebral cavernous malformations

(2014) Changbin Shi et al.   JOURNAL OF NEUROIMMUNOLOGY

Bleeding propensity of cavernous malformations: impact of tight junction alterations on the occurrence of overt hematoma

(2014) Dejan Jakimovski et al.   JOURNAL OF NEUROSURGERY

Cerebral cavernous malformation is a vascular disease associated with activated RhoA signaling

(2012) Bryan T. Richardson et al.   BIOLOGICAL CHEMISTRY

Natural history and imaging prevalence of cavernous malformations in children and young adults

(2012) Wajd N. Al-Holou et al.   Journal of Neurosurgery-Pediatrics

Untreated clinical course of cerebral cavernous malformations: a prospective, population-based cohort study

(2012) Rustam Al-Shahi Salman et al.   LANCET NEUROLOGY

A call for transparent reporting to optimize the predictive value of preclinical research

(2012) Story C. Landis et al.   NATURE

Alemtuzumab more effective than interferon  -1a at 5-year follow-up of CAMMS223 Clinical Trial

(2012) A. J. Coles et al.   NEUROLOGY

Biologics in oral medicine: ulcerative disorders

(2012) ID O’Neill et al.   ORAL DISEASES

Loss ofcerebral cavernous malformation 3(Ccm3) in neuroglia leads to CCM and vascular pathology

(2011) Angeliki Louvi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Fasudil Decreases Lesion Burden in a Murine Model of Cerebral Cavernous Malformation Disease

(2011) David A. McDonald et al.   STROKE

Recent insights into cerebral cavernous malformations: the molecular genetics of CCM

(2010) Florence Riant et al.   FEBS Journal

A novel mouse model of cerebral cavernous malformations based on the two-hit mutation hypothesis recapitulates the human disease

(2010) D. A. McDonald et al.   HUMAN MOLECULAR GENETICS

Rho Kinase Inhibition Rescues the Endothelial Cell Cerebral Cavernous Malformation Phenotype

(2010) Asya L. Borikova et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity

(2010) Rebecca A. Stockton et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review

(2010) L. J. MAXWELL et al.   JOURNAL OF RHEUMATOLOGY

Type I natural killer T cells suppress tumors caused by p53 loss in mice

(2009) J. B. Swann et al.   BLOOD

The cerebral cavernous malformation signaling pathway promotes vascular integrity via Rho GTPases

(2009) Kevin J Whitehead et al.   NATURE MEDICINE

Immune Response in Human Cerebral Cavernous Malformations

(2009) Changbin Shi et al.   STROKE

Complement Activation Is Involved in Renal Damage in Human Antineutrophil Cytoplasmic Autoantibody Associated Pauci-Immune Vasculitis

(2008) Guang-qun Xing et al.   JOURNAL OF CLINICAL IMMUNOLOGY